<DOC>
	<DOC>NCT00151294</DOC>
	<brief_summary>Emotionally labile, depressed participants with multiple sclerosis treated with escitalopram will have a greater reduction in emotional lability scores and in their psychological distress scores than those who are randomized to receive placebo.</brief_summary>
	<brief_title>The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis</brief_title>
	<detailed_description>Patients with multiple sclerosis who are experiencing mood lability and symptoms of depression will be randomized to receive either escitalopram 10mg/day or placebo tablets for a period of 6 weeks. It is hypothesized that patients receiving medication will experience a greater normalization of their emotional instability and a greater reduction in their depressive symptoms at the end of the six-week trial than those who are not receiving medication.</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Clinical diagnosis of multiple sclerosis Having mild to moderate depressive symptoms, with or without emotional lability Experiencing psychological distress Meeting DSMIV diagnostic criteria for Major Depressive Disorder or another Axis 1 diagnosis Cognitive impairment The presence of an unstable medical illness that might preclude completion of the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Depression (mild to moderate)</keyword>
	<keyword>Affective symptoms</keyword>
	<keyword>Emotional lability</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>